Healio Blog: Navigating the Next Frontier in Cellular Therapy Toxicities
As transplantation and cellular therapy continue to evolve, reducing treatment-related toxicities remains one of the field's most important challenges.
Advances in transplantation, chimeric antigen receptor T-cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, and other immune effector cell therapies have expanded treatment opportunities for a growing range of patients.
They also are accompanied by new and increasingly complex toxicity profiles.
To address these challenges, the American Society for Transplantation and Cellular Therapy (ASTCT) will convene the 5th International Conference on Toxicities of Transplantation and Cellular Therapies.
The conference, scheduled for Nov. 13-14 in Chicago, will bring together experts from hematology, oncology, critical care, cardiology, nephrology, infectious disease and other specialties to explore emerging toxicities, multidisciplinary management strategies and future directions in supportive care.
In this Q&A, Sergio A. Giralt, MD, FACP, FASTCT, Melvin Berlin Family Chair in Multiple Myeloma and deputy head of the division of hematologic malignancies at Memorial Sloan Kettering Cancer Center, discusses the origins of the conference, how toxicity management has evolved alongside cellular therapies, the importance of multidisciplinary collaboration, and the opportunities ahead to improve the safety and tolerability of transplantation and cellular therapies for patients worldwide.